Release issued 24th July 2008

Formerly of Harvard University’s office of General Counsel, attorney will be responsible for all legal aspects of the company

July 24, 2008, Waltham, Mass. - Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, announced today that Lori Silver has joined the company as General Counsel, responsible for all legal aspects of the company. Ms. Silver comes to Decision Resources with an impressive array of relevant experience, including five years at the Office of the General Counsel of Harvard University, handling litigation, contracts, intellectual property, computer and internet issues and international operations.

Ms. Silver received a B.A. in Political Science from Stanford University and a J.D. from Harvard Law School. Ms. Silver has chaired the Boston Bar Association's Arts, Entertainment & Sports Law Committee and was named one the Boston area's "Rising Star" lawyers by Boston Magazine in 2006 and 2007.

Ms. Silver is responsible for managing all legal issues related to Decision Resources, Inc.'s business, including commercial agreements, intellectual property, employment, licensing and acquisitions.

"We are very excited that Lori has joined our team," said Peter Hoenigsberg, CEO of Decision Resources. "As Decision Resources, Inc. continues to implement an aggressive growth strategy -both organically and through acquisitions -Lori will be instrumental in helping us achieve our business expansion goals, owing to her wide-range of impressive legal expertise, especially in the areas of intellectual property protection and compliance in general."

About Decision Resources, Inc.
Decision Resources, Inc. is a portfolio of companies that offer best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed, knowledgeable decisions. Decision Resources, Inc. companies include: HealthLeaders-InterStudy, providing insight on the managed care industry (www.HealthLeaders-InterStudy.com); Millennium Research Group, providing analysis on the medical device industry (www.MRG.net); Decision Resources, providing information on the biopharmaceutical industry (www.DecisionResources.com); Arlington Medical Resources (AMR), providing clinical audit data (www.AMR-data.com); Fingertip Formulary, providing U.S. formulary data (www.FingertipFormulary.com); and Manhattan Research, providing global physician and consumer digital market research (www.manhattanresearch.com

(2nd December 2008) Market for cellular therapies will grow at a robust annual rate of more than 30 percent in the United States through 2017

(2nd December 2008) Biologic drugs, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai’s Humira, will drive the Psoriasis drug market to US$5 billion by 2017

(1st December 2008) Humira will overtake Remicade as the Crohn’s Disease market leader by 2012

(1st December 2008) Advair’s patient share in newly diagnosed Asthma patients is declining

(19th November 2008) Uptake of next-generation antifungals has intensified competition in the severe fungal infections drug market